We scan new podcasts and send you the top 5 insights daily.
Dr. Bazanova cites breast cancer data suggesting resistance is driven substantially by the ADC payload. Because most lung cancer ADCs currently available or in development use topoisomerase inhibitors, she expects back-to-back use to work poorly, and she notes many trials often exclude prior topoisomerase exposure.
Dr. Liu highlights that sequentially administering ADCs remains active if clinicians change the cytotoxic payload, even when targeting the identical receptor. Conversely, emerging prospective breast cancer trials indicate that sequencing a topoisomerase I inhibitor ADC directly after another yields very low antitumor response rates.
Data from a novel Nectin-4 ADC trial showed zero responses in patients with prior topoisomerase therapy. This strongly suggests that payload resistance, not just the ADC target, is a critical mechanism that will dictate future treatment sequencing.
When sequencing antibody-drug conjugates, clinical experience suggests that resistance to the chemotherapy payload is a primary driver of failure. Therefore, oncologists tend to avoid using another ADC with the same payload consecutively, preferring to switch both target and payload if possible.
When sequencing antibody-drug conjugates (ADCs), the critical factor for efficacy may not be switching the antibody target, but rather switching the cytotoxic payload. For example, using an ADC with a different payload (like tizotumab vedotin’s MMAE) after one with a topoisomerase inhibitor (like TDXD) could overcome resistance, shifting the paradigm from 'ADC after ADC' to 'payload after payload'.
When sequencing antibody-drug conjugates (ADCs) for SCLC, resistance may be driven more by the cytotoxic payload (e.g., a topoisomerase 1 inhibitor) than the antibody's target antigen. This suggests prior exposure to a similar payload class could predict non-response, even when using an ADC with a different target.
With 18 of 19 ADCs in development for SCLC using a topoisomerase-1 inhibitor payload, there's a significant risk that patients may not respond to a second ADC after progressing on a first. This highlights a critical need to develop ADCs with alternative payloads to provide more therapeutic options and overcome resistance.
As more antibody-drug conjugates (ADCs) become available, a key concern is resistance to the cytotoxic payload. If a tumor develops resistance to a topoisomerase-1 inhibitor from one ADC, it may not respond to other ADCs using the same payload, regardless of their different antibody targets, complicating future treatment sequencing.
When patients progress on an antibody-drug conjugate (ADC), the resistance is frequently due to the tumor becoming resistant to the chemotherapy payload (e.g., a topoisomerase inhibitor). This is more common than the tumor losing the surface target, which critically impacts the sequencing of subsequent ADCs.
Nearly all promising antibody-drug conjugates (ADCs) in late-stage development for small cell lung cancer utilize a topoisomerase-1 (Topo-1) inhibitor payload. This overlap raises a critical clinical question: if a patient develops resistance to one ADC, will they respond to another? This creates a significant challenge for treatment sequencing and patient selection.
Sequencing one Topo-1 payload ADC directly after another yields diminished patient benefit, even when alternating surface targets like TROP-2 and HER2. Dr. Tolaney notes that while some patients still respond, resistance appears predominantly driven by the chemotherapy payload rather than target mutations.